CYTK Cytokinetics Inc

Price (delayed)

$48.3

Market cap

$5.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.4

Enterprise value

$5.7B

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by ...

Highlights
Cytokinetics's quick ratio has decreased by 21% YoY but it has increased by 16% from the previous quarter
Cytokinetics's gross profit has plunged by 96% YoY and by 50% from the previous quarter
The revenue has dropped by 96% year-on-year and by 50% since the previous quarter

Key stats

What are the main financial stats of CYTK
Market
Shares outstanding
104.85M
Market cap
$5.06B
Enterprise value
$5.7B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1,312.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,519.03
Earnings
Revenue
$3.75M
EBIT
-$502.15M
EBITDA
-$489.78M
Free cash flow
-$422.57M
Per share
EPS
-$5.4
Free cash flow per share
-$4.15
Book value per share
-$3.85
Revenue per share
$0.04
TBVPS
$7.93
Balance sheet
Total assets
$808.08M
Total liabilities
$1.2B
Debt
$754.92M
Equity
-$396.16M
Working capital
$549.85M
Liquidity
Debt to equity
-1.91
Current ratio
7.19
Quick ratio
6.98
Net debt/EBITDA
-1.3
Margins
EBITDA margin
-13,053.7%
Gross margin
100%
Net margin
-14,141.7%
Operating margin
-13,272%
Efficiency
Return on assets
-67.3%
Return on equity
N/A
Return on invested capital
-37%
Return on capital employed
-69.8%
Return on sales
-13,383.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYTK stock price

How has the Cytokinetics stock price performed over time
Intraday
-1.39%
1 week
-18.86%
1 month
-27.72%
1 year
26.64%
YTD
-42.15%
QTD
-31.11%

Financial performance

How have Cytokinetics's revenue and profit performed over time
Revenue
$3.75M
Gross profit
$3.75M
Operating income
-$497.97M
Net income
-$530.6M
Gross margin
100%
Net margin
-14,141.7%
The net margin has plunged by 102% from the previous quarter
Cytokinetics's operating margin has plunged by 101% from the previous quarter
Cytokinetics's gross profit has plunged by 96% YoY and by 50% from the previous quarter
The revenue has dropped by 96% year-on-year and by 50% since the previous quarter

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation
P/E
N/A
P/B
N/A
P/S
1,312.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,519.03
The EPS has contracted by 17% YoY
CYTK's equity has dropped by 73% year-on-year and by 2.5% since the previous quarter
The revenue has dropped by 96% year-on-year and by 50% since the previous quarter
CYTK's P/S is 44% above its last 4 quarters average of 912.7

Efficiency

How efficient is Cytokinetics business performance
The ROS has plunged by 102% from the previous quarter
The company's return on assets fell by 47% YoY and by 3.4% QoQ
CYTK's return on invested capital is down by 28% year-on-year and by 2.8% since the previous quarter

Dividends

What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time
The total assets is 33% smaller than the total liabilities
Cytokinetics's quick ratio has decreased by 21% YoY but it has increased by 16% from the previous quarter
The company's current ratio fell by 21% YoY but it rose by 17% QoQ
CYTK's equity has dropped by 73% year-on-year and by 2.5% since the previous quarter
Cytokinetics's debt to equity has increased by 42% YoY and by 2.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.